Arthur D. Little appoints Ulrica Sehlstedt to lead Global Healthcare & Life Sciences Practice
29.10.2019 12:38:00 EET | Business Wire | Press release
Arthur D. Little (ADL) today announced the appointment of Dr. Ulrica Sehlstedt as the new Global Practice Leader for its Global Healthcare & Life Sciences (HCLS) Practice.
With over 20 years of experience in the healthcare and life sciences sectors, Ulrica is a Partner based in ADL’s Stockholm office. She joined the company 13 years ago and has worked extensively for ADL clients across the healthcare and life sciences ecosystem; covering global industry players (pharma, medtech and biotech companies), healthcare providers (public and private), early stage life sciences companies and investors in the sector. Prior to joining ADL, she was CEO of a biotech start-up in molecular diagnostics and also has an extensive background in academic research.
ADL’s Global HCLS Practice works side-by-side with its clients to meet their challenges as the sector goes through an era of enormous medical and technological innovation, while delivering results in a more resource-constrained ecosystem. It achieves this through deep industry knowledge, combined with creative thinking. This enables ADL to work with its clients in harnessing innovation to overcome their most difficult strategic challenges.
Ulrica will take over from Nils Bohlin, who has successfully led the Global HCLS Practice for 8 years, nearly quadrupling its size. After a successful career of 37 years with ADL, Nils has reached retirement age, but will stay in close contact with the company in a new role as Senior Advisor.
Ignacio García Alves, Chairman and Chief Executive Officer at Arthur D. Little comments: “The healthcare and life sciences ecosystem is changing rapidly as innovation and digitalization radically disrupt the sector. At ADL we have already built a strong position in the market, and Ulrica’s leadership will drive further growth in the Global Healthcare & Life Sciences Practice, thanks to her wide experience, deep understanding and commitment to innovation.”
Dr. Ulrica Sehlstedt, Global Practice Leader, Global Healthcare & Life Sciences Practice at Arthur D. Little adds: “While innovation has always been central to healthcare, we are seeing unprecedented change as advances accelerate across the sector. At the same time available resources have not kept pace, meaning that balancing innovation and outcomes requires strategic understanding and market knowledge. ADL’s Global Healthcare and Life Sciences Practice is already perfectly positioned to help our clients meet these challenges, and I look forward to leading the team as the industry transforms.”
Ulrica holds a PhD in biophysics from Stockholm University, as well as an MSc in Chemical Engineering from Chalmers University of Technology, Gothenburg, Sweden. She has also been a member of the Swedish Research Council’s Scientific Council for Medicine for six years, and is regularly engaged in expert roles for life science research and industry initiatives directed towards governments and policy makers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191029005489/en/
Contact information
Cate Bonthuys
Catalyst Comms
+44 7746 56773
cate@catalystcomms.co.uk
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva26.9.2026 02:00:00 EEST | Press release
Mirum Pharmaceuticals, Inc. (Nasdaq:MIRM) and Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Atebrioz™ (zilurgisertib) tablets to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP). The recommended dose of Atebrioz is 100 mg administered orally, once daily. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925436454/en/ “Today marks an important milestone for people living with FOP, bringing a new treatment option to adult and pediatric patients living with this devastating disease,” said Chris Peetz, Chief Executive Officer at Mirum. “At Mirum, we are driven to serve rare disease communities where the unmet need is significant and the opportunity to make a difference is profound. The approval of Atebrioz reflects what can be achieved when industry, researchers
Digital Reef Signs Offtake Agreement with Oreasoc Agriculture to Mitigate the Environmental Footprint of Data Centre Growth Through Rainforest Protection, Appointing Xange.com as Digital MRV Partner25.9.2026 22:19:00 EEST | Press release
At Climate Week NYC, Digital Reef and Oreasoc Agriculture Inc. sign an offtake agreement connecting Digital Reef’s 3.3 GW data centre pipeline with environmental assets exceeding 30 million hectares of South American Amazon rainforest, mitigating the environmental footprint of data centre growth through rainforest protection and restoration where Oreasoc works alongside local communities to protect biodiversity, develop sustainable economies and safeguard their territories. Xange.com are appointed as digital MRV technology partner to monitor the data centres and rainforest where Digital Reef will purchase verified environmental assets generated by Oreasoc, supporting the development of low-carbon data centres mitigating their environmental footprint through the protection of high-integrity natural ecosystems across the South American Amazon, whilst advancing sustainable economic development. AI and data centre demand is driving rapid growth, with the International Energy Agency project
NetApp Announces Intent to Acquire PEAK:AIO to Advance Scalable AI Infrastructure Architecture25.9.2026 16:00:00 EEST | Press release
NetApp® (NASDAQ: NTAP), the intelligent data infrastructure company, today announced its intent to acquire PEAK:AIO, a pioneer in next-generation metadata architecture and high-performance parallel file systems. The planned acquisition is expected to accelerate NetApp's AI infrastructure roadmap by augmenting metadata services and parallel namespace innovation designed to help AI clouds scale shared storage alongside growing GPU clusters. As AI becomes embedded in every enterprise workload, organizations are confronting a new challenge: traditional storage architectures were not designed for the unprecedented scale, concurrency, and performance requirements of AI factories, AI clouds, and next-generation data-intensive applications. NetApp is building an architecture that disaggregates metadata from data and enables metadata services to scale independently, creating a foundation for AI infrastructure capable of supporting trillions of files, exabyte-scale environments, and massively pa
MultiBank Group Secures Two Awards at Forex Expo Dubai 202625.9.2026 15:57:00 EEST | Press release
MultiBank Group, one of the world’s largest financial derivatives institutions, received two awards during its participation at Forex Expo Dubai 2026, held on 22 and 23 September at Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260925539591/en/ MultiBank Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The Group was named “Best Global Institutional Financial Ecosystem of the Year” and received the award for “Excellence in Global Financial Markets Innovation and Community Impact.” The first award recognised the strength and breadth of MultiBank Group’s global institutional offering, which brings together trading, liquidity, technology, infrastructure, execution, market access and tailored client solutions within an integrated financial ecosystem. The second award acknowledg
Croma-Pharma Introduces saypha ® volume prime Lidocaine25.9.2026 15:04:00 EEST | Press release
Croma-Pharma introduces saypha® volume prime Lidocaine, a cross-linked hyaluronic acid dermal filler that replaces saypha® volume Lidocaine within the company's saypha® portfolio. The new product offers physicians a more versatile solution with expanded indications for both midface volumization and nasolabial folds, backed by strong clinical data. 1,2 saypha® volume prime Lidocaine demonstrated non-inferiority to comparatora in a randomized, subject- and evaluator-blinded, controlled, non-inferiority multicenter, parallel group comparison study with almost 500 patients.2 In the clinical evaluation, a high patient satisfaction highlights improved midface fullness, smoothness and contour, consistent with a rheologic profile designed to provide volumization in the mobile midface.b,2 With saypha® volume prime Lidocaine, Croma-Pharma further strengthens its product range, reflecting the company's long-standing commitment to scientific excellence and continuous product innovation, and provid
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom